Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be obtained before any assessment is performed.
Subject was enrolled in the QCC374X2201 study and completed per protocol
You may not be if
Subjects who have started receiving prostacyclin (epoprostenol), prostacyclin analogs (i.e. trepostinil, iloprost, beraprost) or prostacyclin receptor agonists (i.e. selexipag) since the last study drug intake in the QCC374X2201 study.
Females who are pregnant, or who plan to become pregnant during the study, or who are breastfeeding
Any known factor or disease that may interfere with treatment compliance or study conduct (i.e. drug or alcohol dependence)
Subjects who withdrew consent from the study QCC374X2201
Clareo Health | Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
